Viewing Study NCT00695903

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 7:19 PM

Ignite Modification Date: 2025-12-25 @ 4:58 PM

Study NCT ID: NCT00695903

Status: TERMINATED

Last Update Posted: 2018-12-24

First Post: 2008-06-10

Is NOT Gene Therapy: False

Has Adverse Events: True

Brief Title: Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module